Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund
The scheme seeks to invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors.
Growthvine rating: 4/5 — ranked #25 of 245 in category.
Fund basics
| Category | Equity: Index |
|---|
| NAV | ₹23.18 (as of 2026-10-22) |
|---|
| AUM | ₹192 Cr |
|---|
| Expense ratio | 0.90% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Bhavesh Jain |
|---|
| Exit load | 0 |
|---|
Performance & risk
| 5-year annualised return | 12.94% |
|---|
| Sharpe ratio | 0.95 |
|---|
| Standard deviation | 12.53% |
|---|
| Max drawdown | −16.69% |
|---|
| Alpha | 2.2 |
|---|
| Beta | 0.68 |
|---|
Market cap allocation
| Large cap | 45.9% |
|---|
| Mid cap | 50.1% |
|---|
| Small cap | 3.9% |
|---|
Concentration
| Top 5 holdings | 33.7% |
|---|
| Top 10 holdings | 55.0% |
|---|
| Total holdings | 45 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 10.4%
- Divis Laboratories Ltd. — 7.1%
- ELI LILLY & CO — 6.5%
- Apollo Hospitals Enterprises Ltd. — 5.3%
- JOHNSON & JOHNSON — 4.4%
- Laurus Labs Limited — 4.4%
- Torrent Pharmaceuticals Ltd. — 4.4%
- Cipla Ltd. — 4.3%
- Max Healthcare Institute Limited — 4.2%
- Dr. Reddys Laboratories Ltd. — 4.0%
Top sectors
- Pharma & Biotech — 54.3%
- Global Equity — 31.3%
- Healthcare — 14.3%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 11.4% | — | — |
| 2025 | 4.9% | — | — |
| 2024 | 28.9% | — | — |
| 2023 | 24.4% | — | — |
| 2022 | −5.3% | — | — |